To further explore the potential mechanism, we throw the hypothesis that APS may improve diabetic cardiomyopathy with the inhibition of myocardial lipotoxicity dependent on the cardiac PPARα regulatory pathway. The gene discussed is PPARA; the disease is diabetic cardiomyopathy.